Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 11
Partnerships 12
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 12
Licensing Agreements 13
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 13
Equity Offering 15
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 15
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 16
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 18
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 20
ContraVir Pharma Spin Off from Synergy Pharma 21
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 22
Acquisition 23
ContraVir Pharma Acquires Ciclofilin Pharma 23
ContraVir Pharmaceuticals Inc – Key Competitors 24
ContraVir Pharmaceuticals Inc – Key Employees 25
ContraVir Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Corporate Communications 27
Dec 15, 2016: ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors 27
Sep 21, 2016: ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors 28
Mar 31, 2016: ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer 29
Product News 30
12/08/2016: ContraVirs Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B 30
11/07/2016: ContraVir to Present at AASLDs The Liver Meeting 2016 31
05/25/2016: ContraVir to Showcase CMX157 Data in Poster at the 3rd ANRS HBV Cure Workshop 32
04/19/2016: Ciclofilin Pharmaceuticals Invited to Present Hepatitis B Drug Data at Cambridge Healthtech Institute’s Eleventh Annual Drug Discovery Chemistry Conference 33
04/14/2016: ContraVir Invited to Present CMX157 Data at Cambridge Healthtech Institute’s Eleventh Annual Drug Discovery Chemistry Conference 34
04/04/2016: ContraVir Invited to Present CMX157 Data at the Oligonucleotide Therapeutics & Delivery Conference 35
03/03/2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 36
02/04/2016: Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board 37
01/03/2017: ContraVir Awarded Grant from Canada’s National Research Council to Advance CRV431 for the Treatment of Hepatitis B 38
Clinical Trials 39
Dec 19, 2016: ContraVir Expands Phase 2a Trial of Tenofovir Exalidex to Include Doses above 100mg 39
Oct 17, 2016: CMX157 Advances Head-to-Head Phase 2a Clinical Study in Hepatitis B Patients with Favorable Recommendation from DSMB 40
Oct 13, 2016: CMX157 Demonstrates 99% Viral Load Reduction in Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread in Hepatitis B Patients 41
Sep 12, 2016: ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B 43
Aug 22, 2016: ContraVir to Release New CRV431 Data Highlighting Potential Synergy with CMX157 Against Hepatitis B 44
Aug 02, 2016: ContraVir Reports Positive Data from Phase 1b Study of CMX157 45
Jun 21, 2016: ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B 46
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles 47
Jun 01, 2016: ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B 48
Apr 19, 2016: ContraVir Doses First Subject in Phase 1b Clinical Study of CMX157 for Treating Chronic Hepatitis B Infection 49
Mar 29, 2016: ContraVir CMX157 Outperforms Gilead Tenofovir AF Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ContraVir Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 11
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 12
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 13
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 15
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 16
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 18
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 20
ContraVir Pharma Spin Off from Synergy Pharma 21
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 22
ContraVir Pharma Acquires Ciclofilin Pharma 23
ContraVir Pharmaceuticals Inc, Key Competitors 24
ContraVir Pharmaceuticals Inc, Key Employees 25
ContraVir Pharmaceuticals Inc, Subsidiaries 26